Item 2.02 Results of Operations and Financial Condition.

On January 18, 2022, CytoSorbents Corporation, a Delaware corporation (the "Company"), issued a press release and stockholder letter (the "Release") and announced certain preliminary financial results for the quarter and fiscal year ended December 31, 2021. A copy of the Release is furnished herewith as Exhibit 99.1.*

* The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.




Item 8.01 Other Events.

As further described in the Release, the Company has decided to voluntarily end the REFRESH 2-AKI study, which remains blinded, and the CYTATION trial. These decisions were made strictly for business reasons to ensure focus on the vital U.S. STAR-T and STAR-D clinical programs and not as a result of any safety issues.





Item 9.01 Exhibits




(d) Exhibits

Exhibit No. Description


  99.1        Release, dated January 18, 2022
104         Cover Page Interactive Data File (embedded with the Inline XBRL document)

© Edgar Online, source Glimpses